ixekizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5083	1143503-69-8

Description:

Molecule	Description
Synonyms: ixekizumab (genetical recombination) ixekizumab LY2439821 taltz	A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

ixekizumab (genetical recombination)
ixekizumab
LY2439821
taltz

A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.90	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
July 4, 2016	PMDA	Eli Lilly Japan
Feb. 25, 2016	EMA
March 22, 2016	FDA	ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site erythema	582.34	25.28	286	9605	74650	50520583
Injection site pain	521.58	25.28	303	9588	110721	50484512
Therapy interrupted	490.55	25.28	174	9717	19978	50575255
Injection site reaction	486.40	25.28	223	9668	49809	50545424
Injection site swelling	485.44	25.28	211	9680	41562	50553671
Therapy cessation	294.01	25.28	129	9762	25882	50569351
COVID-19	236.02	25.28	134	9757	46528	50548705
Injection site urticaria	172.48	25.28	71	9820	12146	50583087
Injection site pruritus	172.45	25.28	104	9787	40307	50554926
Injection site warmth	154.06	25.28	68	9823	13798	50581435
Psoriasis	141.19	25.28	113	9778	68887	50526346
Injection site rash	140.96	25.28	67	9824	16110	50579123
Drug ineffective	120.93	25.28	391	9500	818942	49776291
Ear infection	108.56	25.28	66	9825	25904	50569329
Sinusitis	86.27	25.28	134	9757	170424	50424809
Tooth infection	64.50	25.28	38	9853	14074	50581159
Nasopharyngitis	64.11	25.28	126	9765	192801	50402432
Pharyngitis streptococcal	63.29	25.28	32	9859	8776	50586457
Fungal infection	63.18	25.28	50	9841	29915	50565318
Psoriatic arthropathy	61.88	25.28	60	9831	46972	50548261
Injection site mass	60.80	25.28	38	9853	15642	50579591
Urticaria	57.51	25.28	96	9795	129465	50465768
Product dose omission issue	57.39	25.28	117	9774	183721	50411512
Injection site bruising	54.27	25.28	50	9841	36718	50558515
Infection	50.37	25.28	107	9784	172847	50422386
Inappropriate schedule of product administration	50.33	25.28	66	9825	71765	50523468
Illness	47.59	25.28	39	9852	24501	50570732
SARS-CoV-2 test positive	45.83	25.28	21	9870	4638	50590595
Surgery	40.59	25.28	39	9852	30166	50565067
Urinary tract infection	40.09	25.28	115	9776	223905	50371328
Therapy non-responder	39.06	25.28	49	9842	50973	50544260
Accidental underdose	38.07	25.28	11	9880	647	50594586
Chronic disease	35.16	25.28	7	9884	80	50595153
Pruritus	34.83	25.28	128	9763	283440	50311793
Injection related reaction	34.53	25.28	10	9881	593	50594640
Influenza	34.03	25.28	62	9829	89476	50505757
Acute kidney injury	33.57	25.28	3	9888	228055	50367178
Upper respiratory tract infection	33.53	25.28	52	9839	65846	50529387
Inflammatory bowel disease	32.22	25.28	15	9876	3435	50591798
Wrong technique in device usage process	30.22	25.28	13	9878	2473	50592760
Demyelinating polyneuropathy	30.10	25.28	9	9882	597	50594636
Injection site cellulitis	27.97	25.28	10	9881	1165	50594068
Hypotension	27.88	25.28	6	9885	235463	50359770
Candida infection	27.21	25.28	28	9863	23495	50571738

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site pain	397.00	31.33	171	5752	32275	29536329
Injection site reaction	381.22	31.33	125	5798	11063	29557541
Injection site erythema	323.82	31.33	117	5806	13839	29554765
Injection site swelling	256.55	31.33	89	5834	9328	29559276
Therapy interrupted	223.55	31.33	78	5845	8308	29560296
Therapy cessation	205.70	31.33	85	5838	14377	29554227
Psoriasis	203.61	31.33	108	5815	32119	29536485
Drug ineffective	143.07	31.33	257	5666	362913	29205691
COVID-19	127.47	31.33	83	5840	35931	29532673
Injection site pruritus	106.08	31.33	41	5882	5808	29562796
Injection site rash	94.31	31.33	33	5890	3531	29565073
Nasopharyngitis	90.25	31.33	83	5840	59582	29509022
Ear infection	83.58	31.33	38	5885	8062	29560542
Sinusitis	68.51	31.33	56	5867	34294	29534310
Infection	66.03	31.33	79	5844	76672	29491932
Pruritus	57.75	31.33	92	5831	116757	29451847
Influenza	57.00	31.33	55	5868	41826	29526778
Injection site warmth	56.25	31.33	19	5904	1827	29566777
Injection site urticaria	50.90	31.33	17	5906	1579	29567025
Inappropriate schedule of product administration	47.05	31.33	51	5872	44421	29524183
Psoriatic arthropathy	45.01	31.33	31	5892	14660	29553944
Wrong technique in device usage process	44.55	31.33	14	5909	1071	29567533
Injection site bruising	43.82	31.33	24	5899	7556	29561048
Product dose omission issue	43.65	31.33	73	5850	96310	29472294
Insurance issue	42.19	31.33	13	5910	932	29567672
SARS-CoV-2 test positive	42.17	31.33	18	5905	3281	29565323
Ejection fraction decreased	40.40	31.33	30	5893	15948	29552656
Fungal infection	39.87	31.33	28	5895	13657	29554947
Injection site mass	39.27	31.33	20	5903	5435	29563169
Rash	39.05	31.33	104	5819	189715	29378889
Acute kidney injury	38.99	31.33	4	5919	265263	29303341
Therapy non-responder	37.23	31.33	38	5885	30873	29537731
Intestinal haemorrhage	36.73	31.33	16	5907	3063	29565541
Cellulitis	35.82	31.33	45	5878	45795	29522809
Illness	35.48	31.33	20	5903	6654	29561950
Arthralgia	33.35	31.33	81	5842	139536	29429068
Knee operation	32.78	31.33	12	5911	1460	29567144

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Therapy interrupted	763.06	23.92	235	10862	19801	64467834
Injection site erythema	439.52	23.92	223	10874	70577	64417058
Injection site pain	429.26	23.92	256	10841	111152	64376483
Injection site swelling	419.78	23.92	183	10914	41170	64446465
Therapy cessation	400.27	23.92	165	10932	32324	64455311
Injection site reaction	395.42	23.92	182	10915	46482	64441153
COVID-19	360.44	23.92	190	10907	64950	64422685
Ear infection	187.77	23.92	88	11009	23316	64464319
Sinusitis	173.56	23.92	166	10931	145762	64341873
Psoriasis	159.04	23.92	117	10980	71586	64416049
Injection site pruritus	145.38	23.92	87	11010	37739	64449896
Nasopharyngitis	134.65	23.92	167	10930	195906	64291729
Injection site warmth	134.48	23.92	59	11038	13403	64474232
Psoriatic arthropathy	110.54	23.92	77	11020	43204	64444431
Drug ineffective	109.61	23.92	354	10743	839893	63647742
Injection site urticaria	108.43	23.92	48	11049	11133	64476502
Injection site rash	107.44	23.92	53	11044	15689	64471946
Illness	101.65	23.92	57	11040	21881	64465754
Infection	96.84	23.92	138	10959	184742	64302893
Product dose omission issue	89.92	23.92	137	10960	194610	64293025
Fungal infection	80.64	23.92	58	11039	34193	64453442
SARS-CoV-2 test positive	74.15	23.92	31	11066	6255	64481380
Pharyngitis streptococcal	73.85	23.92	34	11063	8634	64479001
Tooth infection	70.53	23.92	39	11058	14562	64473073
Surgery	69.23	23.92	49	11048	28164	64459471
Inappropriate schedule of product administration	65.43	23.92	80	11017	92206	64395429
Acute kidney injury	53.70	23.92	7	11090	449233	64038402
Drug interaction	50.36	23.92	3	11094	362080	64125555
Wrong technique in device usage process	47.16	23.92	18	11079	2864	64484771
Injection site bruising	46.20	23.92	43	11054	36330	64451305
Pruritus	43.38	23.92	135	10962	312265	64175370
Cellulitis	43.29	23.92	66	11031	93591	64394044
Inflammatory bowel disease	42.44	23.92	19	11078	4519	64483116
Injection site mass	42.37	23.92	30	11067	17240	64470395
Intentional dose omission	41.46	23.92	20	11077	5632	64482003
Product dispensing error	40.52	23.92	25	11072	11425	64476210
Upper respiratory tract infection	40.49	23.92	56	11041	72729	64414906
Hypotension	38.82	23.92	9	11088	380965	64106670
Wrong schedule	36.87	23.92	9	11088	313	64487322
Localised infection	35.14	23.92	34	11063	30127	64457508
Manufacturing product shipping issue	35.08	23.92	7	11090	93	64487542
Chronic disease	34.81	23.92	7	11090	97	64487538
Influenza	34.45	23.92	64	11033	106467	64381168
Insurance issue	33.54	23.92	14	11083	2812	64484823
Bronchitis	31.08	23.92	62	11035	108681	64378954
Injection related reaction	30.38	23.92	9	11088	658	64486977
Rash	30.21	23.92	157	10940	458392	64029243
Urinary tract infection	30.19	23.92	98	10999	231498	64256137
Intestinal haemorrhage	30.16	23.92	16	11081	5498	64482137
Urticaria	29.67	23.92	73	11024	147244	64340391
Spinal operation	28.57	23.92	16	11081	6117	64481518
Product distribution issue	28.35	23.92	9	11088	829	64486806
Skin disorder	26.39	23.92	28	11069	27652	64459983
Antibiotic therapy	25.06	23.92	8	11089	751	64486884
Confusional state	24.98	23.92	7	11090	261137	64226498
Oral candidiasis	24.87	23.92	25	11072	23187	64464448
Device malfunction	24.64	23.92	22	11075	17611	64470024
Oropharyngeal pain	24.59	23.92	50	11047	88817	64398818

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC13	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
MeSH PA	D003879	Dermatologic Agents
FDA MoA	N0000191494	Interleukin-17A Antagonists
FDA EPC	N0000191495	Interleukin-17A Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ankylosing spondylitis	indication	9631008	DOID:7147
Psoriatic arthritis	indication	156370009	DOID:9008
Plaque psoriasis	indication	200965009
Pustular psoriasis	indication	200973000
Erythrodermic psoriasis	indication	200977004
Non-radiographic axial spondyloarthritis	indication	713777005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-17A	Cytokine	Q16552	IL17_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
BTY153760O	UNII
D10071	KEGG_DRUG
4035606	VANDF
C3489764	UMLSCUI
CHEMBL1743034	ChEMBL_ID
DB11569	DRUGBANK_ID
9467	INN_ID
C549079	MESH_SUPPLEMENTAL_RECORD_UI
7541	IUPHAR_LIGAND_ID
1745099	RXNORM
31578	MMSL
d08425	MMSL
724037000	SNOMEDCT_US
763603002	SNOMEDCT_US
016752	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-1445	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections
TALTZ	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7724	INJECTION, SOLUTION	80 mg	SUBCUTANEOUS	BLA	30 sections